Contraception: A review

International Journal of Clinical Practice

Volumn 52, Issue 2, 1998, Pages 102-105

  Kubba, A A ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b Lambeth Health Care ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; GESTAGEN;

CONTRACEPTION; FEMALE; HORMONE RELEASE; HUMAN; HUMAN RIGHTS; INTRAUTERINE CONTRACEPTIVE DEVICE; MALE; MEDICAL INFORMATION; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; SHORT SURVEY;

CONTRACEPTION; CONTRACEPTIVE DEVICES; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HUMANS; INTRAUTERINE DEVICES; PROGESTINS;

EID: 0031910996     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case control study. Lancet 1995, 346: 1575-1582.
2. World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraception: results of an international multicentre case control study. Lancet 1996: 348: 498-505.
3. World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international case control study. Lancet 1997; 349: 1202-1209.
4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative re-analysis of individual data on 53,297 women with breast cancer and 100,139 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
5. Tzourio C, Tecindrazanarivelo A, Iglesias S et al. Case-control study of migraine and risk of ischaemic stroke in young women. BMJ 1995; 310: 830-833.
6. Lewis MA, Spitzer WO, Heinemann LAJ et al. Lowered risk of dying of heart attack with third generation pill may offset risk of dying from thromboembolism. BMJ 1997; 315: 679-680.
7. World Health Organisation. Facts about once-a-month injectable contraceptives: memorandum from a WHO meeting. Bull WHO 1993; 71(6): 677-689.
8. Tayob Y, Adams J, Jacobs H et al. Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception. Br J Obstet Gynaecol 1985; 92: 1003-1009.
9. Population Reports. New era for injectables. 1995 Series K, No 5.
10. Cundy T, Cornish J, Evans MC et al. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ 1994; 308: 247-248.
11. Anon. Norplant: a contraceptive implant. DTB 1994; 32: 17-19.
12. Farley TMM, Rosenberg MJ, Rowe PJ et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339: 785-788.
13. James N, Wilson S, Hughes S. A pilot study to incorporate chlamydia testing in the management of women anticipating IUD insertion in community clinics. Br J Fam Plan 1997; 23: 16-19.
14. Newton J. Update on intrauterine devices. In: Studd J, Ed. Progress in Obstetrics and Gynaecology, Vol 10. Edinburgh: Churchill Livingstone, 1993.
15. Anderson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper releasing (Nova-T) IUDs during 5 years of use: a randomised comparative trial. Contraception 1994; 49: 56-72.
16. Sturridge F, Guillebaud J. Gynaecological aspects of the levonorgestrel-releasing intrauterine system. Br J Obstet Gynaecol 1997; 104: 285-289.
17. International Study Group on Intrauterine Drug Delivery. The GyneFix implant systems for interval, postabortal and postpartum contraception: a significant advance in long-term reversible contraception. Eur J Contracept Repro Health Care 1997; 2: 1-13.
18. Kubba A, Wilkinson C. Emergency contraception: recommendation for practice. Br J Fam Plan 1998 (in press).